

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 16, 2018

Innovate Biopharmaceuticals, Inc.  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation or organization)

001-37797  
(Commission  
File Number)

27-3948465  
(I.R.S. Employer  
Identification No.)

8480 Honeycutt Road, Suite 120, Raleigh, NC 27615  
(Address of principal executive offices) (Zip Code)

(919) 275-1933  
(Registrant's telephone number, include area code)

N/A  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 5.02.           Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

The employment of June S. Almenoff, M.D., Ph.D., F.A.C.P., Chief Operating Officer and Chief Medical Officer of Innovate Biopharmaceuticals, Inc. (the “Company”), terminated on November 16, 2018. The Company is grateful for Dr. Almenoff’s contributions and is entering into a consulting agreement with her. Dr. Almenoff will receive payments in accordance with the terms of the previously disclosed Executive Employment Agreement, dated March 9, 2018, between the Company and Dr. Almenoff. A copy of such Employment Agreement is attached as Exhibit 10.23 to the Company’s Form 10-K, filed with the Securities and Exchange Commission on March 14, 2018, as amended June 29, 2018.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Innovate Biopharmaceuticals, Inc.

Date: November 23, 2018

By: /s/ Jay P. Madan

Jay P. Madan

President and Chief Business Officer